Advancing immune cell profiling technology

Peripheral blood mononuclear cells (PBMCs): Role and applications

Peripheral Blood Mononuclear Cells (PBMCs) are key immune cells separate from peripheral blood and crucial to the immune response. They identify and eliminate abnormal cells and foreign pathogens to preserve health.

Advancing immune cell profiling technology

Image Credit: ACROBiosystems

Lymphocytes comprise around 70–90 % of the total cell population with PMBCs. They are classified into several groups: T cells (CD3+), B cells (CD3-CD19+), and NK cells (CD3-CD16+CD56+). T cells are separated according to CD4 and CD8 expression into cytotoxic T cells (CD3+CD8+) and helper T cells (CD3+CD4+).

PBMCs are critical in research and clinical settings. They function as a primary cell source for cell therapies like CAR-T. They are crucial in various applications, such as in vitro biomarker detection and tumor immunology, rare disease research, and toxicology. Observing the proportions of different PBMC subpopulations is vital in immune cell therapy applications like CAR-T cell therapy.

The importance of PBMC subpopulation analysis in CAR-T cell therapy

CAR-T cell therapy usually involves the following key stages: 1. identifying the cell source, 2. preparing the cell product, and 3. evaluating therapeutic outcomes. As the main source of CAR-T cells, an awareness of the proportion of various cell types and subpopulations within PBMCs is crucial for directing cell therapy processes, evaluating cell purity, and assessing in vivo efficacy.

Monitoring the proportion of different cells and subpopulations in PBMCs or final products is key to the safety and efficacy of CAR-T cell therapies. Regulatory bodies, including the European Medicines Agency, the China National Medical Products Administration, and the US Food and Drug Administration, stress the need for comprehensive cellular phenotype analysis, including percentages of NK cells, and CD3+, CD4+, and CD8+ T cells.

CAR-T cell products’ quality control standards incorporate characterization, uniformity, and purity testing to ensure and uphold product quality and consistency.

Advancing immune cell profiling technology

Image Credit: ACROBiosystems

Flow cytometry-based immune cell profiling

Immune cell profiling technologies include chip-based assays, qPCR, next-generation sequencing, and flow cytometry. Flow cytometry is most desirable due to its efficiency, high throughput, and precision. It can identify and sort cells based on surface markers through antibody binding and fluorochrome conjugation, facilitating precision quantification of immune cell subpopulations.

This technique’s high sensitivity and specificity make it widely used in clinical sample analysis and basic research.

Introducing the ClinMax Human TBNK 6-color Cocktail Flow Panel

ACROBiosystems proudly presents the ClinMax™ Human TBNK 6-color Cocktail Flow Panel (Cat. No. ICA-A001), a cutting-edge solution for immune cell profiling. This panel, designed using meticulous methodological validation and proprietary technology, offers a reliable means of rapidly detecting T cells, B cells, and NK cells in human whole blood or PBMCs.

Advancing immune cell profiling technology

Image Credit: ACROBiosystems

About ACROBiosystems

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Their mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. They supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, ACROBiosystems delivers solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. ACROBiosystems empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Nov 5, 2024 at 11:13 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2024, November 05). Advancing immune cell profiling technology. News-Medical. Retrieved on December 21, 2024 from https://www.news-medical.net/whitepaper/20241009/Advancing-immune-cell-profiling-technology.aspx.

  • MLA

    ACROBiosystems. "Advancing immune cell profiling technology". News-Medical. 21 December 2024. <https://www.news-medical.net/whitepaper/20241009/Advancing-immune-cell-profiling-technology.aspx>.

  • Chicago

    ACROBiosystems. "Advancing immune cell profiling technology". News-Medical. https://www.news-medical.net/whitepaper/20241009/Advancing-immune-cell-profiling-technology.aspx. (accessed December 21, 2024).

  • Harvard

    ACROBiosystems. 2024. Advancing immune cell profiling technology. News-Medical, viewed 21 December 2024, https://www.news-medical.net/whitepaper/20241009/Advancing-immune-cell-profiling-technology.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.